|
US4733665C2
(en)
|
1985-11-07 |
2002-01-29 |
Expandable Grafts Partnership |
Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
|
|
US5135919A
(en)
|
1988-01-19 |
1992-08-04 |
Children's Medical Center Corporation |
Method and a pharmaceutical composition for the inhibition of angiogenesis
|
|
DE3827340A1
(de)
*
|
1988-08-12 |
1990-02-15 |
Hoechst Ag |
Verwendung von (alpha)-aminoboronsaeure-derivaten zur prophylaxe und behandlung von viruserkrankungen
|
|
JPH0291023U
(cg-RX-API-DMAC10.html)
|
1989-01-05 |
1990-07-19 |
|
|
|
US5441944A
(en)
|
1989-04-23 |
1995-08-15 |
The Trustees Of The University Of Pennsylvania |
Substituted cyclodextrin sulfates and their uses as growth modulating agents
|
|
US5071957A
(en)
|
1989-08-04 |
1991-12-10 |
Bristol-Myers Company |
Antibiotic BU-4061T
|
|
US4990448A
(en)
|
1989-08-04 |
1991-02-05 |
Bristol-Myers Company |
Bu-4061T
|
|
KR0166088B1
(ko)
|
1990-01-23 |
1999-01-15 |
. |
수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
|
|
US5376645A
(en)
|
1990-01-23 |
1994-12-27 |
University Of Kansas |
Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
|
|
IE910713A1
(en)
|
1990-03-05 |
1991-09-11 |
Cephalon Inc |
Chymotrypsin-like proteases
|
|
US5340736A
(en)
|
1991-05-13 |
1994-08-23 |
The President & Fellows Of Harvard College |
ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting
|
|
GB9300048D0
(en)
|
1993-01-04 |
1993-03-03 |
Wellcome Found |
Endothelin converting enzyme inhibitors
|
|
TW380137B
(en)
|
1994-03-04 |
2000-01-21 |
Merck & Co Inc |
Process for making an epoxide
|
|
US5693617A
(en)
|
1994-03-15 |
1997-12-02 |
Proscript, Inc. |
Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
|
|
US6660268B1
(en)
|
1994-03-18 |
2003-12-09 |
The President And Fellows Of Harvard College |
Proteasome regulation of NF-KB activity
|
|
US6506876B1
(en)
|
1994-10-11 |
2003-01-14 |
G.D. Searle & Co. |
LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use
|
|
US6083903A
(en)
|
1994-10-28 |
2000-07-04 |
Leukosite, Inc. |
Boronic ester and acid compounds, synthesis and uses
|
|
DE19505263A1
(de)
|
1995-02-16 |
1996-08-22 |
Consortium Elektrochem Ind |
Verfahren zur Reinigung von wasserlöslichen Cyclodextrinderivaten
|
|
US6335358B1
(en)
|
1995-04-12 |
2002-01-01 |
President And Fellows Of Harvard College |
Lactacystin analogs
|
|
US6150415A
(en)
|
1996-08-13 |
2000-11-21 |
The Regents Of The University Of California |
Epoxide hydrolase complexes and methods therewith
|
|
AU4499697A
(en)
|
1996-09-13 |
1998-04-02 |
New York University |
Method for treating parasitic diseases with proteasome inhibitors
|
|
DE69709671T2
(de)
|
1996-10-18 |
2002-08-22 |
Vertex Pharmaceuticals Inc., Cambridge |
Inhibitoren von serinproteasen, insbesondere von ns3-protease des hepatitis-c-virus
|
|
SI0932617T1
(en)
|
1996-10-18 |
2002-06-30 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
|
|
US5874418A
(en)
|
1997-05-05 |
1999-02-23 |
Cydex, Inc. |
Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
|
|
US6046177A
(en)
|
1997-05-05 |
2000-04-04 |
Cydex, Inc. |
Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
|
|
ES2210769T3
(es)
|
1997-06-13 |
2004-07-01 |
Cydex Inc. |
Compuesto con vida de almacenamiento prolongada que comprende ciclodextrina y medicamentos y promedicamentos que se descomponen en componentes insolubles en agua.
|
|
US6133308A
(en)
|
1997-08-15 |
2000-10-17 |
Millennium Pharmaceuticals, Inc. |
Synthesis of clasto-lactacystin beta-lactone and analogs thereof
|
|
US6075150A
(en)
|
1998-01-26 |
2000-06-13 |
Cv Therapeutics, Inc. |
α-ketoamide inhibitors of 20S proteasome
|
|
US6099851A
(en)
|
1998-06-02 |
2000-08-08 |
Weisman; Kenneth M. |
Therapeutic uses of leuprolide acetate
|
|
US6902721B1
(en)
|
1998-07-10 |
2005-06-07 |
Osteoscreen, Inc. |
Inhibitors of proteasomal activity for stimulating bone growth
|
|
US6462019B1
(en)
|
1998-07-10 |
2002-10-08 |
Osteoscreen, Inc. |
Inhibitors of proteasomal activity and production for stimulating bone growth
|
|
US6838436B1
(en)
|
1998-07-10 |
2005-01-04 |
Osteoscreen Inc. |
Inhibitors of proteasomal activity for stimulating bone growth
|
|
US6204257B1
(en)
|
1998-08-07 |
2001-03-20 |
Universtiy Of Kansas |
Water soluble prodrugs of hindered alcohols
|
|
AU762373B2
(en)
|
1998-10-20 |
2003-06-26 |
Millennium Pharmaceuticals, Inc. |
Method for monitoring proteasome inhibitor drug action
|
|
US6492333B1
(en)
|
1999-04-09 |
2002-12-10 |
Osteoscreen, Inc. |
Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
|
|
US6831099B1
(en)
|
1999-05-12 |
2004-12-14 |
Yale University |
Enzyme inhibition
|
|
EP1716861A3
(en)
|
1999-10-20 |
2007-08-29 |
Osteoscreen, Inc. |
Inhibitors of proteasomal activity for stimulating bone and hair growth
|
|
DK1326632T3
(da)
|
2000-10-12 |
2007-01-15 |
Viromics Gmbh |
Protease-inhibitorer til behandling af infektioner af hepatitisvirus
|
|
EP1355910B1
(en)
|
2001-01-25 |
2011-03-09 |
The United States of America, represented by the Secretary, Department of Health and Human Services |
Formulation of boronic acid compounds
|
|
WO2002094311A1
(en)
|
2001-05-21 |
2002-11-28 |
Alcon, Inc. |
Use of proteasome inhibitors to treat dry eye disorders
|
|
BR0210112A
(pt)
*
|
2001-05-30 |
2004-06-08 |
Novartis Ag |
Derivados do ácido 2-{[n-(2-amino-3-(heteroarila ou arila)propionil)-aminoacil]-amino}-alquilborÈnico
|
|
WO2003059898A2
(en)
|
2002-01-08 |
2003-07-24 |
Eisai Co. Ltd. |
Eponemycin and epoxomicin analogs and uses thereof
|
|
US20040116329A1
(en)
|
2002-01-29 |
2004-06-17 |
Epstein Stephen E. |
Inhibition of proteasomes to prevent restenosis
|
|
AU2003220685A1
(en)
|
2002-04-09 |
2003-10-27 |
Greenville Hospital System |
Metastasis modulating activity of highly sulfated oligosaccharides
|
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
|
AU2003249682A1
(en)
|
2002-06-03 |
2003-12-19 |
Als Therapy Development Foundation |
Treatment of neurodegenerative diseases using proteasome modulators
|
|
US20030224469A1
(en)
|
2002-06-03 |
2003-12-04 |
Buchholz Tonia J. |
Methods and kits for assays utilizing fluorescence polarization
|
|
US20040167139A1
(en)
|
2002-07-26 |
2004-08-26 |
Potter David A. |
Methods of treating cancer
|
|
US7189740B2
(en)
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
|
TW200418791A
(en)
|
2003-01-23 |
2004-10-01 |
Bristol Myers Squibb Co |
Pharmaceutical compositions for inhibiting proteasome
|
|
CA2521325C
(en)
|
2003-04-08 |
2010-09-14 |
Novartis Ag |
Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol
|
|
CA2528120A1
(en)
|
2003-06-10 |
2005-01-20 |
The J. David Gladstone Institutes |
Methods for treating lentivirus infections
|
|
US7012063B2
(en)
|
2003-06-13 |
2006-03-14 |
Children's Medical Center Corporation |
Reducing axon degeneration with proteasome inhibitors
|
|
AU2004312096A1
(en)
|
2003-12-31 |
2005-07-21 |
Cydex Pharmaceuticals, Inc. |
Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
|
|
GB0400804D0
(en)
|
2004-01-14 |
2004-02-18 |
Innoscience Technology Bv |
Pharmaceutical compositions
|
|
US7232818B2
(en)
|
2004-04-15 |
2007-06-19 |
Proteolix, Inc. |
Compounds for enzyme inhibition
|
|
US8198270B2
(en)
|
2004-04-15 |
2012-06-12 |
Onyx Therapeutics, Inc. |
Compounds for proteasome enzyme inhibition
|
|
WO2005105827A2
(en)
|
2004-04-15 |
2005-11-10 |
Proteolix, Inc. |
Compounds for proteasome enzyme inhibition
|
|
JP5108509B2
(ja)
|
2004-05-10 |
2012-12-26 |
プロテオリックス， インコーポレイテッド |
酵素阻害のための化合物
|
|
AU2005243140A1
(en)
|
2004-05-10 |
2005-11-24 |
Proteolix, Inc. |
Synthesis of amino acid keto-epoxides
|
|
EP2100899A3
(en)
|
2004-10-20 |
2009-09-30 |
Proteolix, Inc. |
Compounds for proteasome enzyme inhibition
|
|
KR101299821B1
(ko)
|
2004-12-07 |
2013-09-03 |
프로테올릭스, 인코퍼레이티드 |
프로테아좀 저해를 위한 조성물
|
|
US7468383B2
(en)
|
2005-02-11 |
2008-12-23 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
|
WO2006099261A2
(en)
*
|
2005-03-11 |
2006-09-21 |
The University Of North Carolina At Chapel Hill |
Potent and specific immunoproteasome inhibitors
|
|
EP1876893B1
(en)
|
2005-04-15 |
2012-04-11 |
Geron Corporation |
Cancer treatment by combined inhibition of proteasome and telomerase activities
|
|
GT200600350A
(es)
|
2005-08-09 |
2007-03-28 |
|
Formulaciones líquidas
|
|
MX2008006090A
(es)
|
2005-11-09 |
2008-10-23 |
Proteolix Inc |
Compuestos para inhibicion de la enzima.
|
|
AR057227A1
(es)
|
2005-12-09 |
2007-11-21 |
Centocor Inc |
Metodo para usar antagonistas de il6 con inhibidores del proteasoma
|
|
US20070207950A1
(en)
|
2005-12-21 |
2007-09-06 |
Duke University |
Methods and compositions for regulating HDAC6 activity
|
|
WO2007122686A1
(ja)
|
2006-04-14 |
2007-11-01 |
Eisai R & D Management Co., Ltd. |
ベンズイミダゾール化合物
|
|
DE102006026464A1
(de)
|
2006-06-01 |
2007-12-06 |
Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma |
Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
|
|
RU2450016C2
(ru)
|
2006-06-19 |
2012-05-10 |
Протеоликс, Инк. |
Пептидные эпоксикетоны для ингибирования протеасомы
|
|
WO2008033807A2
(en)
|
2006-09-13 |
2008-03-20 |
The Arizona Board Of Regents On Behalf Of The University Of Arizona |
Synergistic combinations of antineoplastic thiol-binding mitochondrial oxidants and antineoplastic proteasome inhibitors for the treatment of cancer
|
|
EP2117556A2
(en)
|
2007-01-23 |
2009-11-18 |
Gloucester Pharmaceuticals, Inc. |
Combination therapy comprising romidepsin and i.a. bortezomib
|
|
WO2008140782A2
(en)
|
2007-05-10 |
2008-11-20 |
Proteolix, Inc. |
Compounds for enzyme inhibition
|
|
US7442830B1
(en)
|
2007-08-06 |
2008-10-28 |
Millenium Pharmaceuticals, Inc. |
Proteasome inhibitors
|
|
KR20150010802A
(ko)
|
2007-08-06 |
2015-01-28 |
밀레니엄 파머슈티컬스 인코퍼레이티드 |
프로테아좀 억제제
|
|
KR20160086980A
(ko)
|
2007-10-04 |
2016-07-20 |
오닉스 세라퓨틱스, 인크. |
결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
|
|
WO2009051581A1
(en)
|
2007-10-16 |
2009-04-23 |
Millennium Pharmaceuticals, Inc. |
Proteasome inhibitors
|
|
US7838673B2
(en)
|
2007-10-16 |
2010-11-23 |
Millennium Pharmaceuticals, Inc. |
Proteasome inhibitors
|
|
US20090131367A1
(en)
|
2007-11-19 |
2009-05-21 |
The Regents Of The University Of Colorado |
Combinations of HDAC Inhibitors and Proteasome Inhibitors
|
|
KR101691093B1
(ko)
|
2008-06-17 |
2016-12-29 |
밀레니엄 파머슈티컬스 인코퍼레이티드 |
보로네이트 에스테르 화합물 및 이의 제약학적 조성물
|
|
AR075090A1
(es)
|
2008-09-29 |
2011-03-09 |
Millennium Pharm Inc |
Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
|
|
MX2011004225A
(es)
|
2008-10-21 |
2011-06-21 |
Onyx Therapeutics Inc |
Terapia de combinacion con epoxicetonas peptidicas.
|
|
AR075899A1
(es)
|
2009-03-20 |
2011-05-04 |
Onyx Therapeutics Inc |
Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
|
|
CN101928329B
(zh)
*
|
2009-06-19 |
2013-07-17 |
北京大学 |
三肽硼酸(酯)类化合物、其制备方法和应用
|
|
WO2011060179A1
(en)
|
2009-11-13 |
2011-05-19 |
Onyx Therapeutics, Inc |
Use of peptide epoxyketones for metastasis suppression
|
|
BR112012022060A2
(pt)
*
|
2010-03-01 |
2018-05-08 |
Onyx Therapeutics Inc |
composto para a inibição de imunoproteassoma
|
|
MX2012011298A
(es)
|
2010-03-31 |
2012-11-06 |
Millennium Pharm Inc |
Derivados del acido 1-amino-2-ciclopropiletilboronico.
|
|
EP2555621A4
(en)
|
2010-04-07 |
2014-07-02 |
Onyx Therapeutics Inc |
CRYSTALLINE EPOXYCETONE PEPTIDE IMMUNOPROTEASOME INHIBITOR
|
|
FR2962092B1
(fr)
*
|
2010-06-30 |
2013-06-28 |
Valeo Systemes Dessuyage |
Adaptateur d'essuie-glace a contacts electriques
|